Ann: CEO Appointment , page-17

New CEO certainly distancing himself from ipo failure at end of last year

"Walker told CFO launching the listing at the end of the year was not good timing particularly in a strong year for biotechnology listings, with many fund managers unwilling to take on more risk from the sector.

“Nothing has changed except the timing,” he said. “It is a major market for our lead product. The markets and the doctors are there. We will bide our time and not set ourselves up [again] for such a public fall.”